W., Yamamoto, H
For example, emerging protein targets like IL-4, IL-10, IL-15, IL-17, IL-18, IL-23, interleukin-1 receptor-associated kinase (IRAK)-4 have been revealed to have a strong implication with innate and adaptive immune response in RA ( Protein Targets for Treatment of Rheumatoid Arthritis Currently, many agents aiming at various protein targets have been explored and tested to ease the progression of RA, and some agents have been used in the clinic to treat RA patients ( Table 1 )
Tirzepatide has demonstrated substantial weight loss in clinical trials, with patients losing an average of 15-21% of body weight over 72 weeks
As for interleukin, IL-17 and IL-1b act by inhibiting cell-specific melanosomal proteins and activating T helper-17 cells, which increase cell damage by causing mitochondrial dysfunction [19]
So, early diagnosis is essential